Aardvark Therapeutics, INC Form 4 insider transactions

Aardvark Therapeutics' Chief Financial Officer, Nelson Sun, was granted 70,549 stock options with an exercise price of $13.48, vesting over several years.

Aardvark Therapeutics' Chief Medical Officer, Manasi Jaiman, was granted 70,549 stock options with a $13.48 exercise price, vesting over several years.

Aardvark Therapeutics' CEO, Tien-Li Lee, was granted 203,851 stock options with an exercise price of $13.48, vesting over several years.

Aardvark Therapeutics' Chief Financial Officer, Nelson Sun, acquired 3,000 shares of common stock at $14.4 per share in a pre-planned transaction.

Aardvark Therapeutics CEO and 10% owner, Lee Tien-Li, plans to acquire 7,000 shares of common stock at $14.485 per share.

Aardvark Therapeutics CEO, Tien-Li Lee, exercised options to acquire 1,229 shares of common stock at $4.24 per share, increasing direct ownership.

Aardvark Therapeutics' Chief Operating Officer, Bryan Jones, exercised options to acquire 1,250 shares of common stock at $4.24 per share.

Aardvark Therapeutics CEO and 10% owner Tien-Li Lee purchased 10,000 shares of common stock for approximately $96,800.

Aardvark Therapeutics' CEO and 10% owner, Tien-Li Lee, increased direct beneficial ownership by purchasing 20,000 shares of common stock for approximately $160,654 over three days in September 2025.

Aardvark Therapeutics' Chief Financial Officer, Nelson Sun, purchased 6,000 shares of common stock at an average price of $8.0733.

Aardvark Therapeutics CEO Tien-Li Lee exercised stock options to acquire 17,209 shares of common stock at $4.24 per share, increasing direct ownership.

Aardvark Therapeutics, Inc. CEO and Director, Tien-Li Lee, was granted 549,534 stock options with an exercise price of $11.29, vesting over several years, as disclosed in a recent SEC Form 4 filing.

Aardvark Therapeutics, Inc. Director Jeffrey Chi was granted 61,017 stock options with an exercise price of $11.29, aligning his interests with the company's long-term performance.

Aardvark Therapeutics, Inc.'s Chief Medical Officer, Manasi Jaiman, was granted 126,999 stock options with an exercise price of $11.29, vesting over four years.

Roy D. Baynes, a Director at Aardvark Therapeutics, Inc., was granted 30,508 stock options with an exercise price of $11.29, vesting on June 11, 2026.

Aardvark Therapeutics, Inc. Director Victor Edward Tong Jr. was granted 61,017 stock options with an exercise price of $11.29, vesting over a multi-year period.

Aardvark Therapeutics, Inc. Chief Financial Officer Nelson Sun was granted 209,826 stock options with an exercise price of $11.29, vesting over four years.

Aardvark Therapeutics, Inc. Chief Operating Officer Bryan Jones has been granted 122,033 stock options with an exercise price of $11.29 per share, vesting over four years.

Aardvark Therapeutics, Inc. Director Susan E. Graf was granted 30,508 stock options with an exercise price of $11.29, vesting in full on June 11, 2026.

Decheng Capital Global Life Sciences Fund IV, L.P. and related entities report changes in beneficial ownership of Aardvark Therapeutics common stock and convertible preferred stock following the company's IPO.

Director Jeffrey Chi reports the conversion of Series C Convertible Preferred Stock to Common Stock in connection with Aardvark Therapeutics' IPO.

Vickers Venture Fund VI Pte Ltd reports the conversion of Series A and B Convertible Preferred Stock into common stock following Aardvark Therapeutics' initial public offering.

Following Aardvark Therapeutics' IPO, CEO Tien-Li Lee reports changes in beneficial ownership, including the conversion of Series A Convertible Preferred Stock into common stock.

CFO Nelson Sun reports acquisition of Aardvark Therapeutics common stock and conversion of Series C Convertible Preferred Stock.

Cormorant Asset Management reports changes in beneficial ownership of Aardvark Therapeutics stock following the company's initial public offering.